AI In Pharma Summit

AI In Pharma Summit

October 9th, 2019  |  Boston, MA.

DATA-DRIVEN, PEOPLE-POWERED.

UNLOCKING THE FULL POTENTIAL OF AI IN DRUG DISCOVERY AND DEVELOPMENT

Registration Agenda

Partners

Knowledge Partner
Knowledge Partner

BioSymetrics empowers healthcare and biomedical R&D innovation.
Augusta™ is the first biomedical specific machine learning framework and programming language designed to increase precision, shorten timelines and improve discovery.  Successful projects range from drug discovery and research to diagnostics, precision medicine and value-based care.

 

Learn More

Knowledge Partner

Cyclica is a Toronto-based biotechnology company that leverages biophysics and artificial intelligence (AI) to make drug discovery faster, safer, and cheaper. We enable all scientists in Pharma with an integrated network of technologies, thereby driving drug discovery and revolutionizing a system troubled with attrition and costly failures.

Our cloud-based Ligand Express® platform uncovers the polypharmacological profiles of small molecules to provide insight into target identification, mechanism of drug action, lead prioritization, the elucidation of adverse effects, and drug repurposing. We are extending the capabilities of Ligand Express® to include structural pharmacogenomics by layering annotated genetic data on top of protein structure in order to help investigate the effect of genetic variation on drug action. These capabilities have also been augmented by the addition of ADMET Prediction tool, an adaptive AI modelling methodology that outperforms traditional classifiers to generate QSAR models, thereby enabling a better understanding of the relationship between drug structure and function.

 

Learn More

Knowledge Partner

Deep Lens is an AI company focused on enabling faster recruitment of the best-suited patients for clinical trials at the time of diagnosis using VIPER.  Deep Lens’ AI-driven cloud platform gives care teams, trial coordinators and oncologists visibility into all available trials and the ability to collaborate on groundbreaking cancer research across all cancer types.

 

Learn More

Knowledge Partner

Life Image is the largest global evidence network specializing in ‘living’ data sets of novel imaging that’s linkable to other clinical information. Founded in 2008, the company is now integrated into the workflows of 80% of large academic medical centers, connecting 10,000 facility endpoints with 150,000 U.S. providers and 58,000 global clinics. Life Image provides data access and network distribution for an interoperable network ecosystem of hospitals, physicians, patients, pharmaceuticals, medical device, telehealth and EHRs.

 

Learn More

Knowledge Partner
Knowledge Partner

Wuxi NextCODE:WuXi NextCODE is a global genomic data and insights company. We serve the world’s leading life sciences companies by providing access to population-scale patient cohorts for research, NGS CLIA/CAP GCP labs globally and a team of leading A.I. and genomic analysis experts for organizing, mining and sharing genomic and disease biology data.

 

Learn More

Key features of AI IN PHARMA
Pioneering Speaker Faculty

High-Quality Data Infrastructure, the “Right” use of AI and Machine Learning will all be put under the microscope by key opinion leaders of the industry.

One Impactful Day of Learning

We know you’re busy people. That’s why the AI in Pharma Summit is purposely constructed as a one-day feast of inspiring learning with a jam-packed agenda.

Senior-Level Networking

With speed-networking, hands-on workshops and long-table lunches the order of the day, meet with key decision-makers and AI champions in this purpose-built, intimate setting.

2019 Speakers

Vanita Sood
Vanita Sood
Global Head of Drug Structure, Prediction & Design
EMD Serono
Vanita Sood
Global Head of Drug Structure, Prediction & Design
EMD Serono

As Global Head of Design, Structure, Prediction & Data science (DSPD), Vanita supports drug discovery (small molecule and biologics) with a global team of computational chemists, structural biologists, computational protein engineers, and data scientists.

Calum Macrae
Calum Macrae
Vice Chair for Scientific Innovation
Brigham and Women's Hospital & Harvard Medical School
Calum Macrae
Vice Chair for Scientific Innovation
Brigham and Women's Hospital & Harvard Medical School
Brian Martin
Brian Martin
Head of AI
AbbVie
Brian Martin
Head of AI
AbbVie
Pat Walters
Pat Walters
Senior Vice President, Computation
Relay Therapeutics
Pat Walters
Senior Vice President, Computation
Relay Therapeutics

Pat Walters is SVP of Computation at Relay Therapeutics in Cambridge, MA. His group focuses on novel applications of computational methods that integrate computer simulations and experimental data to provide insights that drive drug discovery programs. Prior to joining Relay, Pat spent more than 20 years at Vertex Pharmaceuticals where he was Global Head of Modeling & Informatics.

Lina Williamson
Lina Williamson
Founder & Chief Innovation Officer
Translational Medicine Accelerator
Lina Williamson
Founder & Chief Innovation Officer
Translational Medicine Accelerator

Dr Williamson holds a DVM in animal dermatology and a PhD in human molecular and cellular dermato-pathology of autoimmune skin diseases from the University of Bern in Switzerland. She initiated her career at Novartis Pharmaceuticals in Switzerland where she had the opportunity to create and lead the Animal Dermatology Research group at Novartis Animal Health. Lina was later transferred to Boston in an international assignment to the Novartis Institutes for Biomedical Research (NIBR) as part of a cross-divisional business development team. She later joined NIBR’s Strategic Alliances team where she was responsible for leading the global outreach and scouting for innovation efforts from academic institutions, including academic incubators and startup companies. During that time, she developed interest on cutting edge technologies in the biomedical engineering field. That interest led her to join a startup company – Emulate Inc., derived from Harvard University’s Wyss Institute, focused on the development of Organs-on-Chips – and be part of the initial company creation team. Dr. Williamson joined the Brigham and Women’s Hospital in 2015, initially supporting the Brigham Research Institute as Innovation Strategists. Her entrepreneurial and strategic thinking & execution style, combined with more than twelve years of experience in the Pharma/Biotech industry, led her to take the challenge of create and establish the BWH Translational Accelerator, an initiative to support and speed up the transition of BWH’s innovation with commercial potential from bench to bed. Dr. Williamson currently serves as Founder, President & Chief Innovation Officer of the Translational Medicine Accelerator (TMA), a private biomedical development company formed to accelerate medical innovation that serves patients with unmet needs. Lina is also part of the NIH National Networks of Mentors in Entrepreneurship, a mentor for the post-doc program at Boston Children’s Hospital and supports entrepreneurship education programs from the Harvard Catalyst (Harvard Medical School).

Leo Rodrigues
Leo Rodrigues
Vice President, AI and Machine Learning
Berg Health
Leo Rodrigues
Vice President, AI and Machine Learning
Berg Health
Constantine Kreatsoulas
Constantine Kreatsoulas
Director of Molecular Design US
GSK
Constantine Kreatsoulas
Director of Molecular Design US
GSK
Birgit Schoeberl
Birgit Schoeberl
Global Head Modeling and Simulation, PK Sciences
Novartis
Birgit Schoeberl
Global Head Modeling and Simulation, PK Sciences
Novartis

Dr. Birgit Schoeberl currently serves as Global Head of Modeling and Simulation, PK Sciences at Novartis. Before joining Novartis, Birgit served as interim Senior Vice President, Scientific Value, at GNS Healthcare. During her time at GNS, she focused on applying causal machine learning to drug development. Prior to GNS, she was a member of the founding team at Merrimack Pharmaceuticals and where she spent over 12 years in different roles. In her latest role as Head of Discovery and Early Development, she gained broad experience in oncology drug discovery and development. Birgit and her leadership team were responsible for multiple preclinical and early clinical programs.

Birgit received her Chemical Engineering degree from the Technical University in Karlsruhe, Germany, and her Ph.D. in Biological Engineering from the Max Planck Institute for Dynamics of Complex Technical Systems in Magdeburg. She was a post-doctoral fellow in the laboratories of Douglas Lauffenburger and Peter Sorger in the Biological Engineering Department at MIT.

Naheed Kurji
Naheed Kurji
President and CEO
Cyclica
Naheed Kurji
President and CEO
Cyclica
Janak Joshi
Janak Joshi
Chief Technology Officer
Life Image
Janak Joshi
Chief Technology Officer
Life Image

Janak Joshi is a three-time entrepreneur successfully raising capital, building and selling companies with the mission of fixing healthcare. Janak has been co-founder and CIO at Synestesi Technologies (sold to Spry Media Group), CIO at Generation Health (sold to CVS Caremark), and CEO at Type I Diabetes Exchange before his current role as CTO and Head of Strategy at Life Image.

Sameen Desai
Sameen Desai
Director of Pharmacovigilance Innovation
Celgene
Sameen Desai
Director of Pharmacovigilance Innovation
Celgene

Sameen has over 20 years of experience in Pharmaceutical Industry. He has a degree in Chemical Engineering, a Masters in Business Administration and a Masters in Information Systems. He has worked in several functions including manufacturing, IT, regulatory and quality. He is a Senior Director at Celgene with a focus on Innovation within Pharmacovigilance(PV). He has authored several publications around use of AI & emerging technology within PV.

Gabriel Musso
Gabriel Musso
Chief Scientific Officer
BioSymetrics
Gabriel Musso
Chief Scientific Officer
BioSymetrics

Experienced data scientist and award-winning educator. Chief Scientific Officer of BioSymetrics, Gabe is responsible for pioneering the use of artificial intelligence for biomedical research. Gabe’s experience includes using machine learning frameworks to predict gene and small molecule function, and identification of disease-causal genes using large-scale genomic datasets.

Tom Chittenden
Tom Chittenden
Chief AI Scientist
WuXi NextCODE
Tom Chittenden
Chief AI Scientist
WuXi NextCODE
Wei Fan
Wei Fan
Executive Director of Tencent Medical AI Labs
Tencent
Wei Fan
Executive Director of Tencent Medical AI Labs
Tencent

2019 Agenda

  • Wednesday, October 9th
Wednesday, October 9th
8.00am
Registration, Breakfast & Networking
9.00am
Chair’s Opening Remarks & Setting the Scene

Lina Williamson, Founder & Chief Innovation Officer, Translational Medicine Accelerator

09:10am
Presentation: Intelligent Systems for Discovery, Translation and Implementation

Calum Macrae, Vice Chair of Scientific Innovation, Brigham and Women’s Hospital & Harvard Medical School

9:35am
Presentation by Cyclica

Naheed Kurji, President and CEO, Cyclica

10:00am
Panel Discussion and Open Q&A: Is AI Always Going to be Limited by Data and is Collaboration the Key to Tackle this Issue?

Pat Walters, Senior Vice President, Computation, Relay Therapeutics

Gabriel Musso, Chief Scientific Officer, BioSymetrics

Vanita Sood, Global Head of Drug Structure, Prediction & Design, EMD Serono

10:40am
Morning Refreshments & Speed Networking
11:30am
Presentation: Unconventional Machine Learning of Genome-wide Human Cancer Data

Tom Chittenden, Chief AI Scientist, WuXi NextCODE

11:55am
Presentation: How To Ensure We Are Using AI The “Right” Way

Brian Martin, Head of AI, AbbVie

12:20am
Panel Discussion and Open Q&A: When and Where is the Right Time to Use AI

Bino John, Associate Director, Data Science – Clinical Pharmacology and Safety Sciences, AstraZeneca

Kyle Flickinger, Vice President, BioPharmaceutical Solutions, Deep Lens

Sameen Desai, Director of Pharmacovigilance Innovation, Celgene

Leo Rodrigues, Vice President, AI and Machine Learning, Berg Health

1:00pm
Long-Table Lunch & Networking
Interactive Workshops

During these intimate breakout sessions, attendees will discuss the key questions surrounding AI and machine learning in pharma. Through deep-dive discussions, examples and peer-to-peer learning, these interactive workshops will allow attendees to uncover answers to questions that are not possible through presentations and panels… The topics in session A and B will remain the same;  giving you the opportunity to participate in two sessions. You are spoilt for choice!

2:00pm
Workshops Sessions A
Workshop 1A: Leveraging Artificial Intelligence to Further Healthcare

 

 

Led by one of the industry’s most passionate leaders, this workshop will bring in your own real world data to help demonstrate the true capabilities of AI when applied to healthcare

 

Emmanuel Fombu, Global Strategy and Digital Innovation Leader, Johnson & Johnson

Workshop 2A: Understanding the Importance of Clean, Usable Data and Underpinning the Significance of Data Sharing

 

This workshop will allow you to be fully clued up on the importance of using quality data to produce quality results and also discuss if data sharing is truly the way forward for the industry.

 

Janak Joshi, Chief Technology Officer, Life Image

Time to Switch!
2:40pm
Workshops Sessions B
Workshop 1B: Leveraging Artificial Intelligence to Further Healthcare

 

 

Led by one of the industry’s most passionate leaders, this workshop will bring in your own real world data to help demonstrate the true capabilities of AI when applied to healthcare

 

Emmanuel Fombu, Global Strategy and Digital Innovation Leader, Johnson & Johnson

Workshop 2B: Understanding the Importance of Clean, Usable Data and Underpinning the Significance of Data Sharing

 

This workshop will allow you to be fully clued up on the importance of using quality data to produce quality results and also discuss if data sharing is truly the way forward for the industry.

 

Janak Joshi, Chief Technology Officer, Life Image

3:20pm
Afternoon Refreshments & Networking

Use Cases – How is AI Being Used in the Field for More Specialised Tasks?

4:00pm
Presentation: Inventing Better Drug - Use of AI & Machine Learning in Small Molecule & Biologics Discovery

Vanita Sood, Global Head of Drug Structure, Prediction & Design, EMD Serono

4:25pm
Presentation: Personalized Precision Medicine, a Patient-Scientist Perspective

Lina Williamson, Founder & Chief Innovation Officer, Translational Medicine Accelerator

Looking Ahead and Critical Questions

4:50pm
Panel Discussion: With Artificial Intelligence at the Peak of its Hype Curve, Can Machine Learning Live Up to Expectations?

Birgit Schoeberl, Global Head Modeling and Simulation, PK Sciences, Novartis

Armaghan Naik, AVP R&D Scientific & Digital Innovation, Sanofi

Constantine Kreatsoulas, Director of Molecular Design US, GSK

5:30pm
Chair’s Closing Remarks

Lina Williamson, Founder & Chief Innovation Officer, Translational Medicine Accelerator

5:40
Drinks Reception
6:40pm
End of AI in Pharma Summit 2019
Download Agenda

Partner With Us

The 2018 summit exceeded all expectations and the 2019 summit is attracting considerable interest.

The success of the 2018 summit was down to the high-class programme and the quality of the audience. Registrations were only accepted from applicants who were appropriate for the summit and delegates from vendor companies were not permitted.

This ensured that the audience of senior decision makers were able to meet with a selected group of relevant suppliers. Our 2018 partners tell us that they made significant inroads into target companies and advanced their sales pipelines.

For further information, or to have an informal discussion regarding partnership opportunities, please contact Zanib Malik on (+44) 20 8051 3811 or zanib@greygreenmedia.com

Contact Us +
Partner With Us

Register for the Event

For pricing and booking options please click the button to go to the registration page.

Registration